A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Kidney Transplant Failure and Rejection
Interventions
DRUG

Imlifidase

This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.

Trial Locations (6)

10016

New York University School of Medicine, New York

17176

Karolinska University Hospital, Stockholm

21205

The Johns Hopkins Hospital, Baltimore

75743

Necker Hospital, Paris

90048

Cedars-Sinai Medical Center, Los Angeles

751 85

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT03611621 - A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation | Biotech Hunter | Biotech Hunter